Overview

Cadonilimab Combination With Chemotherapy With or Without AK117 in Resectable Gastric or Gastroesophageal Junction Adenocarcinoma

Status:
Recruiting

Trial end date:
2027-11-30

Target enrollment:

Participant gender:

Summary

This trial is a Phase II study. All patients are resectable Gastric or Gastroesophageal Junction Adenocarcinoma, Eastern Cooperative Oncology Group (ECOG) performance status 0-1.The purpose of this study is to evaluate the efficacy and safety of cadonilimab combined with chemotherapy with or without AK117 neoadjuvantin treatment of resectable Gastric or Gastroesophageal Junction Adenocarcinoma.

Phase:

Phase 2

Details

Lead Sponsor:

Akeso

Treatments:

Docetaxel
Fluorouracil
Oxaliplatin
Tegafur